Endocrine disrupting compounds and prostate cancer.
Prostate cancer is a major health concern and is treated based on its hormone dependence. Agents that alter hormone action can have substantial biological effects on prostate cancer development and progression. As such, there is significant interest in uncovering the potential effects of endocrine disrupting compound (EDC) exposure on prostate cancer. The present review is focused on agents that alter hormone action in the prostate and how they may impact cancer growth or treatment.
Hess-Wilson
J K
JK
Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Ave., Cincinnati, OH 45267-0521, USA.
Knudsen
K E
KE
D000728:Androgens / Q000502:physiology; D004032:Diet; D052244:Endocrine Disruptors / Q000008:administration & dosage / Q000633:toxicity*; D006801:Humans; D008297:Male; D009153:Mutagens; D011467:Prostate / Q000254:growth & development; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000503:physiopathology; D011944:Receptors, Androgen / Q000502:physiology
D000728:Androgens; D052244:Endocrine Disruptors; D009153:Mutagens; D011944:Receptors, Androgen